IP Library Granted Patent US 10,907,188
Granted Patent B2
US 10,907,188 · App. 16/093,074 · Granted Feb 2, 2021

Compositions and methods for the production of compounds

Inventors: Brian R. Bowman (New Rochelle, NY); Joshua A. V. Blodgett (Webster Groves, MO); Gregory L. Verdine (Boston, MA); Daniel C. Gray (Medford, MA); Jay P. Morgenstern (Boston, MA); Lucy Foulston (Medford, MA); Keith Robison (Andover, MA)
Assignee: Ginkgo Bioworks, Inc.
C12P35/00C07K14/36C12N15/52C12N15/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,907,188
App. No.
16/093,074
Granted
Feb 2, 2021
Kind
B2
Abstract

The present disclosure provides nucleic acids encoding a Large ATP-binding regulator of the LuxR family (LAL) of transcription factors, vectors and host cells including such nucleic acids, and methods for producing compounds (e.g., polyketides or β-lactam compounds) with such nucleic acids, vectors, and/or host cells.

Claims (35)

1. A genetically modified host cell comprising:

(i) a nucleic acid encoding a recombinant Large ATP-binding regulator of the LuxR family (LAL) that is heterologous to the host cell; and

(ii) a nucleic acid comprising an LAL binding site that is heterologous to the host cell.

2. The host cell of claim 1 , wherein the host cell naturally lacks an LAL or the host cell naturally lacks an LAL binding site.

3. The host cell of claim 1 , wherein the LAL binding site is operably linked to an open reading frame.

4. The host cell of claim 3 , wherein the open reading frame encodes a compound-producing protein.

5. The host cell of claim 1 , wherein:

the recombinant LAL comprises a portion having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1;

the recombinant LAL comprises a portion having the amino acid sequence of SEQ ID NO: 1; or

the recombinant LAL has the amino acid sequence of SEQ ID NO: 1.

6. The host cell of claim 4 , wherein the host cell has been modified to enhance expression of the compound-producing protein by (i) deletion of an endogenous gene cluster which expresses an endogenous compound-producing protein; (ii) insertion of a heterologous gene cluster which expresses a heterologous compound-producing protein; (iii) exposure of the host cell to an antibiotic challenge; and/or (iv) introduction of a heterologous promoter that results in an at least 2-fold increase in expression of a compound produced by the compound-producing protein compared to the expression of the compound when the homologous promoter has not been replaced.

7. The host cell of claim 1 , wherein:

the nucleic acid further comprises one or more additional LAL binding sites;

at least one of the LAL binding sites is in a promoter; or

the nucleic acid further comprises a gene encoding an LAL.

8. The host cell of claim 7 , wherein:

the gene encoding an LAL is under the control of a promoter comprising an LAL binding site; or

at least one of the LAL binding sites is in a promoter.

9. The host cell of claim 8 , wherein at least one of the LAL binding sites is in a promoter and the promoter is a bidirectional promoter.

10. A nucleic acid comprising an LAL binding site and a sequence encoding an LAL, wherein the LAL binding site comprises a sequence having no more than one insertion, deletion, or substitution with respect to the nucleic acid sequence of SEQ ID NO:2 and/or comprises the nucleic acid sequence of SEQ ID NO: 3, and wherein

the LAL comprises a portion having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1;

the LAL comprises a portion having the amino acid sequence of SEQ ID NO: 1; or

the LAL has the amino acid sequence of SEQ ID NO: 1.

11. The nucleic acid of claim 10 , wherein the nucleic acid lacks a TTA inhibitory codon in at least one open reading frame.

12. The nucleic acid of claim 10 , wherein the LAL binding site comprises the nucleic acid sequence of SEQ ID NO:2.

13. The nucleic acid of claim 10 , wherein the nucleic acid further comprises an open reading frame.

14. The nucleic acid of claim 13 , wherein the open reading frame encodes a compound-producing protein.

15. The nucleic acid of claim 14 , wherein the compound-producing protein is a polyketide synthase, a β-lactam compound-producing protein, or a non-ribosomal peptide synthase.

16. The nucleic acid of claim 10 , wherein:

the nucleic acid further comprises one or more additional LAL binding sites; or

the gene encoding the LAL is under the control of a promoter comprising an LAL binding site.

17. The nucleic acid of claim 16 , wherein at least one of the LAL binding sites is in a promoter.

18. The nucleic acid of claim 17 , wherein the promoter is a bidirectional promoter.

19. An expression vector comprising a nucleic acid of claim 10 .

20. A host cell comprising the nucleic acid of claim 10 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2019
From: WARP DRIVE BIO, INC.
To: GINKGO BIOWORKS, INC.
Reel/Frame 048956/0611 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2018
From: BOWMAN, BRIAN R.; BLODGETT, JOSHUA A.V.; VERDINE, GREGORY L.; GRAY, DANIEL C.; MORGENSTERN, JAY P.; FOULSTON, LUCY; ROBISON, KEITH
To: WARP DRIVE BIO, LLC
Reel/Frame 047757/0942 →
MERGER Recorded Dec 12, 2018
From: WARP DRIVE BIO, LLC
To: WARP DRIVE BIO, INC.
Reel/Frame 047757/0971 →
Continuity (2)
Provisional Application 62321439 · Apr 12, 2016
Related Publication 20190136284A1 · May 9, 2019